Skip to main content
. 2023 Oct 12;6(10):e2337348. doi: 10.1001/jamanetworkopen.2023.37348

Figure 1. Trends in Weighted Average Price (WAP) per Unit for Rituximab, Bevacizumab, and Trastuzumab Biosimilars Compared With Reference Drugs Between 2015 and 2022.

Figure 1.

Orange dotted lines represent the year bevacizumab, rituximab, and trastuzumab were included on the National Reimbursement Drug List. B indicates biosimilar; R, reference.